兴齐眼药 (300573)
Shenyang Xingqi Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 24642.95
- Circulating A-Shares(W): 18953.13
- Earnings Per Share(RMB): 2.4400
- Net Assets Per Share(RMB): 7.5700
- Operating Revenue(W RMB): 190372.88
- Total Profit(W RMB): 68877.09
- Net Profit Attributable to Parent(W RMB): 59890.64
- Net Profit Growth Rate(%): 105.98
- Weighted Return on Equity(%): 32.9100
- Operating Cash Flow Per Share(RMB): 2.3420
- Undistributed Profit Per Share(RMB): 2.9170
- Capital Reserve Per Share(RMB): 3.2958
2. Main Business
The main business covers:
- Ophthalmic drug research and development
- Ophthalmic drug production
- Ophthalmic drug sales
3. Company Basic Information
- Company Name: Shenyang Xingqi Pharmaceutical Co., Ltd.
- Listing Date: 2016-12-08
- Industry: Pharmaceutical Manufacturing
- Address: 30F, Block B, Enterprise Plaza, No.125 Qingnian Street, Shenhe District, Shenyang City, Liaoning Province
- Website: www.sinqi.com
- Company Profile: Xingqi Eye Medicine was established as a joint stock company through the overall change of Xingqi Co., Ltd.'s audited net assets as of August 31, 2011. On October 28, 2011, the Foreign Trade and Economic Cooperation Bureau of Shenyang Economic and Technological Development Zone issued the "Approval on the Increase of Capital and Conversion of Shenyang Xingqi Pharmaceutical Co., Ltd. into a Foreign-invested Joint Stock Company and Renaming". On November 28, 2011, the company completed the industrial and commercial change registration at the Shenyang Administration for Industry and Commerce and obtained the "Business License of Legal Person" with registration number 210100401000628, with a registered capital of RMB 60 million.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 712.64 | 3.78 |
| 2 | CSI 500 ETF | Fund | 250.63 | 1.33 |
| 3 | China Life Insurance Company Limited - Traditional - General Insurance Product - 005L-CT001 Hu | General Legal Person | 63.43 | 0.34 |
| 4 | Nuode Quality Consumption 6-month Holding Hybrid Securities Investment Fund | Fund | 11.90 | 0.06 |
| 5 | Huashang Innovation Medical Care Hybrid Securities Investment Fund Class A | Fund | 3.31 | 0.02 |
| 6 | Zheshang Huijin Emerging Consumption Flexible Allocation Hybrid Securities Investment Fund | Fund | 1.09 | 0.01 |
| 7 | China Merchants Guozheng 2000 Index Enhanced Securities Investment Fund Class A | Fund | 0.83 | 0.00 |
| 8 | Invesco Great Wall Guozheng 2000 Index Enhanced Securities Investment Fund Class A | Fund | 0.57 | 0.00 |
| 9 | ChinaAMC ChiNext ETF Feeder Fund Class A | Fund | 0.01 | 0.00 |
5. Concept Sectors
- Innovative Drugs
- Margin Trading & Securities Lending
- High-performing Stocks
- Small-cap Growth
- SZSE Growth
- ChiNext 300
- SZSE Innovation
- ChiNext Innovation
- ChiNext Growth
- ChiNext Quality
- ChiNext Pharmaceuticals
- ChiNext 200
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information